Valeant increases Allergan bid as it sells assets to Nestlé
This article was originally published in Clinica
Executive Summary
Valeant Pharmaceuticals has increased its bid for Allergan and sold five dermatology assets to Nestlé for $1.4bn, a move which puts Valeant in a stronger position to acquire Allergan.